Skip to main content
. 2024 Sep 15;14(9):4523–4536. doi: 10.62347/DVXL1377

Figure 6.

Figure 6

MRTX1133 treatment of 3D culture and transgenic mouse organoid models. (A, B) 3D spheroid structure and synergistic drug effects on spheroid models with G12D and G12V with MRTX1133 and ONC212. (C) Synergistic inhibition of pERK in treated (T) versus control (C) tumor cells. (D) Synergistic suppression of pERK after 5-FU and MRTX1133 treatment of transgenic organoids with tamoxifen inducible knockout of APC, knock-in of KRAS G12D, and p53+/- (left) or tamoxifen-inducible knockout of APC, knock-in of KRAS G12D, and p53+/- (right) at 72 hours. (E) 72 h CellTiterGlo loss of cell viability of KRAS G12D spheroids with combinations of MRTX1133 and ONC212 as an example. (F) Spheroid schematic with necrotic core, quiescent layer and proliferating zone.